oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
Örebro University, Orebro University School of Business, Örebro University, Sweden.ORCID iD: 0000-0003-1113-7478
The Dental and Pharmaceutical Benefits Agency (TLV), Stockholm, Sweden.
The Dental and Pharmaceutical Benefits Agency (TLV), Stockholm, Sweden.
2015 (English)In: PharmacoEconomics (Auckland), ISSN 1170-7690, E-ISSN 1179-2027, Vol. 33, no 11, 1229-1236 p.Article in journal (Refereed) Published
Abstract [en]

The Swedish Dental and Pharmaceutical Benefits Agency (TLV) is the government body responsible for deciding whether outpatient drugs are to be included in the pharmaceutical benefits scheme. This paper analyzes the impact of cost effectiveness and severity of disease on reimbursement decisions for new pharmaceuticals.

Data has been extracted from all decisions made by the TLV between 2005 and 2011. Cost effectiveness is measured as the cost per quality-adjusted life-year (QALY) gained, whereas disease severity is a binary variable (severe-not severe). In total, the dataset consists of 102 decisions, with 86 approved and 16 declined reimbursements.

The lowest cost per QALY of declined reimbursements is Swedish kronor (SEK) 700,000 (a,not sign79,100), while the highest cost per QALY of approved reimbursements is SEK1,220,000 (a,not sign135,600). At a cost per QALY of SEK702,000 Swedish kronor (non-severe diseases) and SEK988,000 (severe diseases), the likelihood of approval is estimated to be 50/50 (a,not sign79,400 and a,not sign111,700).

The TLV places substantial weight on both the cost effectiveness and the severity of disease in reimbursement decisions, and the implied willingness to pay for a QALY is higher than the often cited 'rule of thumb' in Swedish policy debates.

Place, publisher, year, edition, pages
Adis International Ltd , 2015. Vol. 33, no 11, 1229-1236 p.
National Category
Economics and Business
Identifiers
URN: urn:nbn:se:oru:diva-46505DOI: 10.1007/s40273-015-0307-6ISI: 000363067200008PubMedID: 26093889Scopus ID: 2-s2.0-84944516806OAI: oai:DiVA.org:oru-46505DiVA: diva2:872018
Note

Funding Agency:

Swedish Research Council for Health, Working Life and Welfare

Available from: 2015-11-17 Created: 2015-11-16 Last updated: 2015-11-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Svensson, Mikael
By organisation
Orebro University School of Business, Örebro University, Sweden
In the same journal
PharmacoEconomics (Auckland)
Economics and Business

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 200 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf